Eli Lilly And Company

This study tested a new drug called LY3405105 in 54 people with advanced solid tumors to see if it was safe. The trial was stopped early. The main goal was to find side effects and, in a later part, to see if the drug could shrink tumors. Participants had to have advanced cancer …

This early-stage study tested a new drug called LY3127804, given alone or with another drug (ramucirumab), in 62 people with advanced solid tumors. The goal was to find a safe dose, but the study was stopped early because no safe dose could be determined. Participants had to have…

This early-stage study tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and fatty liver disease (NAFLD). The main goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.

This study tested a drug called peresolimab in adults with moderate-to-severe rheumatoid arthritis, a condition causing joint pain and swelling. The goal was to see if the drug safely reduces symptoms like joint tenderness and swelling compared to a placebo. About 491 people took…

This study tested an experimental drug called LY3540378 in 332 adults with worsening chronic heart failure with preserved ejection fraction (HFpEF). The goal was to see if the drug could improve heart function and safety compared to a placebo. The study was terminated early, so f…

This study aimed to see if the drug baricitinib is safe and works well for children aged 1 to 18 hospitalized with COVID-19. It involved kids who needed extra oxygen. The trial was stopped early after only 6 participants, so results are limited.

This study tested the safety and effectiveness of the drug lasmiditan for treating migraines in children aged 6 to 17. Over 12 months, researchers tracked side effects and how well the drug relieved pain and other symptoms. The study was stopped early, but results may still help …

This study tested whether the drug lasmiditan can safely relieve migraine pain in children aged 6 to 17. Over 800 participants were enrolled, but the trial was stopped early. The goal was to see if the medicine helps children become pain-free after a migraine attack.